

Drug assessment at a glance: A26-12¹

Sotatercept (pulmonary arterial hypertension, WHO functional class IV)

24 August 2026

¹ This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-12. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Adults with WHO functional class IV pulmonary arterial hypertension (PAH)
Intervention	sotatercept in combination with other treatments for PAH
Comparator	epoprostenol in combination with ERAs (ambrisentan, bosentan, macitentan) and PDE5is (sildenafil, tadalafil)
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects	Informative value of the effects
Mortality	↔	—
Morbidity	↑ (disease worsening)	★
Symptoms	Individuals with a REVEAL Lite 2.0 risk score of ≥ 11: ↑ (dyspnoea)	★
Health-related quality of life	∅	—
Side effects	↔	—
	∅ ↔ ↑ / ↓ ↑↑ / ↓↓ ↑↑↑ / ↓↓↓↓	No (suitable) data No advantage or disadvantage Small advantage/disadvantage Moderate advantage/disadvantage Large advantage/disadvantage
		— ★ ★★ ★★★
		Not applicable Low Moderate High

Overall: An advantage of unclear magnitude with low informative value

Evidence base and noteworthy aspects


- Evidence base: the completed double-blind RCT ZENITH comparing sotatercept with placebo, each in combination with background PAH therapy (relevant subpopulation: patients with WHO functional class IV, N = 20 vs. 24)
- Given the unusual nature of the available data, the existing uncertainties regarding the comparator therapy did not entirely call the observed effects into question.

Key study findings

Study	sotatercept + background therapy		placebo + background therapy		sotatercept + background therapy vs. placebo + background therapy
Outcome category					
Outcome	N	Median time to event [95% CI] Patients with event n (%)	N	Median time to event [95% CI] Patients with event n (%)	HR [95% CI]; p-value
ZENITH (2nd data cut from 6 June 2025)					
Mortality					
Overall survival					
Main analysis	20	NA [25.4; NC] 3 (15.0)	24	NA 3 (12.5)	0.68 [0.11; 4.19]; 0.679
Sensitivity analysis	20	NA [25.4; NC] 4 (20.0)	24	NA 5 (20.8)	0.78 [0.20; 3.00]; 0.717
Morbidity					
Disease worsening	20	NA [25.4; NC] 5 (25.0)	24	9.5 [5.3; NC] 14 (58.3)	0.25 [0.08; 0.78]; 0.017
Health-related quality of life			Outcome category not recorded		
Side effects					
SAEs	20	46.4 [10.3; NC] 12 (60.0)	24	23.1 [11.9; 55.0] 17 (70.8)	0.71 [0.34; 1.49]; 0.365
Discontinuation due to AEs	20	NA 0 (0)	24	NA 1 (4.2)	NC; 0.374


Kaplan-Meier curves on overall survival

ZENITH study, main analysis



Study: ZENITH (MK-7962-006) (Database Cutoff Date: 06JUN2025)
Overall Survival
This figure includes all-cause deaths up to the study completion, except for those occurring after lung transplantation or enrollment in SOTERIA.

ZENITH study, sensitivity analysis



Study: ZENITH (MK-7962-006) (Database Cutoff Date: 06JUN2025)
Overall Survival (Sensitivity Analysis (Y96) Include All Deaths)
This figure includes all-cause deaths up to the data cutoff date, including deaths after lung transplantation or after enrollment in SOTERIA.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sotatercept (pulmonale arterielle Hypertonie, WHO-Funktionsklasse IV); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 06.08.2026]. URL: <https://doi.org/10.60584/A26-12>.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sotatercept (pulmonale arterielle Hypertonie, WHO-Funktionsklasse IV); Addendum zum Projekt A26-12 (Dossierbewertung) [online]. 2026 [Accessed: 06.08.2026]. URL: <https://doi.org/10.60584/A26-75>.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Sotatercept (Neues Anwendungsgebiet: Pulmonale arterielle Hypertonie, WHO-Funktionsklasse IV) [online]. 2026 [Accessed: 06.08.2026]. URL: <https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1313/>.

English translations for this project are published at <https://www.iqwig.de/en/projects/a26-12.html> and <https://www.iqwig.de/en/projects/a26-75.html>.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237

50679 Köln

Germany

Phone: +49 221 35685-0

Fax: +49 221 35685-1

Email: info@iqwig.de

Internet: www.iqwig.de